Detalles de la búsqueda
1.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
N Engl J Med
; 385(27): 2531-2543, 2021 12 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965338
2.
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.
BMC Med Res Methodol
; 22(1): 49, 2022 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35184739
3.
Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.
J Antimicrob Chemother
; 72(9): 2587-2595, 2017 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28673027
4.
Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.
J Trop Pediatr
; 63(2): 135-143, 2017 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27634175
5.
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
J Antimicrob Chemother
; 71(10): 2918-27, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27342546
6.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Lancet Child Adolesc Health
; 7(10): 718-727, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37562418
7.
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial.
EClinicalMedicine
; 60: 102025, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37304494
8.
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial.
J Int AIDS Soc
; 26(9): e26174, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37766505
9.
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Lancet HIV
; 9(5): e341-e352, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35189082
10.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Lancet HIV
; 9(9): e638-e648, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055295
11.
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
PLoS One
; 13(4): e0196239, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29684092
12.
HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda.
AIDS Res Hum Retroviruses
; 32(7): 628-35, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26723018
13.
Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
AIDS Res Hum Retroviruses
; 29(3): 449-55, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23308370
14.
Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
AIDS Res Hum Retroviruses
; 29(6): 925-30, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23517497
Resultados
1 -
14
de 14
1
Próxima >
>>